Strides Pharma Science Limited announced today that its wholly-owned subsidiary, Strides Alathur Private Limited, has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its formulations facility in Alathur, Chennai.
The EIR confirms the successful conclusion of a Good Manufacturing Practices (GMP) inspection conducted from April 1–5, 2024.
The shares of Strides Pharma Science Limited were trading at ₹1,298.15 down by ₹14.70 or (1.12 per cent) on NSE at 11:55 am on Monday.
The USFDA classified the inspection outcome as “Voluntary Action Indicated” (VAI). This facility, which produces tablets and capsules for the U.S. and other regulated markets, is crucial for Strides’ current and future product offerings in the United States.
SHARE
Published on August 19, 2024
Images are for reference only.Images and contents gathered automatic from google or 3rd party sources.All rights on the images and contents are with their legal original owners.
Comments are closed, but trackbacks and pingbacks are open.